Clinical importance of basal insulin analogues and insulin Toujeo^® 300 units/ml

Česká verzia

Authors: Alena Adamíková
Authors place of work: Diabetologické centrum Interní kliniky Krajské nemocnice T. Bati, a. s., Zlín, přednosta MUDr. Jiří Latta
Published in the journal: Vnitř Lék 2015; 61(11): 985-988
Category: Reviews

Summary

Type 2 diabetes mellitus is a heterogeneous disease that requires a personalized approach to treatment with goals tailored to capabilities and abilities of the patient, his other diseases so as to ensure good diabetes control without the risk of hypoglycemic events and the development or progression of late diabetic complications. Recommendations for treatment of diabetes is classified in second-line as a one of the possibilities of treatment of basal insulin immediately after the failure of therapy with metformin and diet. The new generation of basal insulin analogues provides its effect profile and features a completely new quality to the treatment of diabetes. Toujeo^® 300 units/ml is a new long-acting basal insulin glargine concentration of 300 units/ ml with a low glycemic variability, which in studies has demonstrated consistent control of diabetes in a significant reduction in the risk of hypoglycemia especially at night compared with insulin glargin of concentration 100 units/ml.

Key words:
basal insulin analogues – personalized approach – Toujeo^® 300 units/ml – type 2 diabetes mellitus

Zdroje

1. Khunti K, Wolden ML, Thorsted BL et al. Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people. Diabetes Care 2013; 36(11): 3411–3417.

2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-control with sulphonylureas or insulin compared with convential treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352(9131: 837–853. Erratum in Lancet 1999; 354(9178): 602.

3. Del Prato S. Megatrials in type 2 diabetes: from excitement to frustration? Diabetologia 2009; 52(7): 1219–1226.

4. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach. Diabetes Care 2015; 38(1): 140–149.

5. Gerstein HC, Bosch J, Dagenais GR et al. The ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012; 367(4): 319–328.

6. Becker RHA, Dahmen R, Bergmann K et al. New insulin glargine 300 units.mL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 units.mL-1. Diabetes Care 2014; 38(4): 637–643. Dostupné z DOI: <http://dx.doi.org/10.2337/dc14–0006>.

7. Riddle MC, Bolli GB, Yki-Järvinen H et al. One-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal-time insulin: the EDITION 1 12-month randomized trial, including 6-month extension. Diabetes Obes Metab 2015; 17(9):835–842. Dostupné z DOI: <http://dx.doi.org/10.1111/dom.12472>.

8. Yki-Järvinen H, Bergenstal RM, Bolli GB et al. Less nocturnal hypoglycaemia and weight gain with new insulin glargine 300 U/mL vs 100 U/mL: 1-year results in people with type 2 diabetes using basal insulin + OADs (EDITION 2). Abstract 946. Diabetologia 2014; 57(Suppl 1): S387.

9. Bolli GB, Riddle MC, Bergenstal RM et al. New insulin glargine 300 U/mL compared with glargine 100 U/mL in insulin-naive people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3). Diabetes Obes Metab 2015; 17(4): 386–394. Dostupné z DOI: <http://dx.doi.org/10.1111/dom.12438>.

10. Home PD, Bergenstal RM, Riddle MC et al. Glycemic control and hypoglycemia with new insulin glargine 300 U/mL in people with T1DM (EDITION 4). Diabetologia 2014; 57(Suppl 1): S69.

11. Matsuhisa M, Koymama M, Cheng X et al (EDITION JP 1 Study Group). New insulin glargine 300 U/mL: glycemic control and hypoglycemia in Japanese people with T1DM. Diabetologia 2014; 57(Suppl 1): S400.

12. Terauchi Y, Koyama M, Cheng XN et al (EDITION JP 2 Study Group). Glycemic control and hypoglycemia in Japanese people with T2DM receiving new insulin glargine 300 U/mLin combination with OADs. Diabetologia 2014; 57(Suppl 1): S401.

13. SPC TOUJEO 300 jednotek/ml. Dostupné z WWW: <http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/000309/WC500047935.pdf>.

14. Ritzel R, Roussel R, Bolli GB et al. Patient-level meta-analysis of EDITION 1, 2 and 3 studies: glycemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes. Diabetes Obes Metab 2015; 17(9): 859–867. Dostupné z DOI: <http://dx.doi.org/10.1111/dom.12485>.

15. Dailey G, Lavernia F. A review of the safety and efficacy data for insulin glargine 300 units/ml, a new formulation of insulin glargine. Diabetes Obes Metab 2015; 17(12): 1107–1114. Dostupné z DOI: <http://dx.doi.org/10.1111/dom.12531>.